# SARS-CoV-2 incidence and risk factors in a national, community-based prospective cohort of U.S. adults

Denis Nash<sup>1,2</sup>, Madhura S. Rane<sup>1</sup>, Mindy Chang<sup>1</sup>, Sarah Gorrell Kulkarni<sup>1</sup>, Rebecca Zimba<sup>1,2</sup>, William You<sup>1</sup>, Amanda Berry<sup>1</sup>, Chloe Mirzayi<sup>1,2</sup>, Shivani Kochhar<sup>1</sup>, Andrew Maroko<sup>1,3</sup>, McKaylee M. Robertson<sup>1</sup>, Drew A. Westmoreland<sup>1</sup>, Angela M. Parcesepe<sup>1,4,5</sup>, Levi Waldron<sup>1,2</sup>, and Christian Grov<sup>1,6</sup>

#### **AFFILIATIONS:**

#### **CONFLICTS OF INTEREST:** None declared

**KEYWORDS:** COVID-19; serology, seroconversion, asymptomatic infection, physical distancing; natural history study, epidemiologic study, essential workers, public health interventions, community transmission

# **CORRESPONDING AUTHOR:**

Denis Nash, Ph.D., MPH CUNY Graduate School of Public Health and Health Policy 55 W. 125th St., 6th Floor New York, NY USA 10027 Phone: +1-917-740-8714

Email: denis.nash@sph.cuny.edu

Twitter: @epi dude

Fax: +1-866-792-7203

<sup>&</sup>lt;sup>1</sup>Institute for Implementation Science in Population Health (ISPH), City University of New York (CUNY); New York City, New York USA

<sup>&</sup>lt;sup>2</sup>Department of Epidemiology and Biostatistics, Graduate School of Public Health and Health Policy, City University of New York (CUNY); New York City, New York USA

<sup>&</sup>lt;sup>3</sup>Department of Environmental, Occupational, and Geospatial Health Sciences, Graduate School of Public Health and Health Policy, City University of New York (CUNY); New York City, New York USA

<sup>&</sup>lt;sup>4</sup>Department of Maternal and Child Health, Gillings School of Public Health, University of North Carolina, Chapel Hill, NC, USA

<sup>&</sup>lt;sup>5</sup>Carolina Population Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA

<sup>&</sup>lt;sup>6</sup>Department of Community Health and Social Sciences, Graduate School of Public Health and Health Policy, City University of New York (CUNY); New York City, New York USA

#### **ABSTRACT**

# **Background**

Epidemiologic risk factors for incident SARS-CoV-2 infection as determined via prospective cohort studies greatly augment and complement information from case-based surveillance and cross-sectional seroprevalence surveys.

#### **Methods**

We estimated the incidence of SARS-CoV-2 infection and risk factors in a well-characterized, national prospective cohort of 6,738 U.S. adults, enrolled March-August 2020, a subset of whom (n=4,510) underwent repeat serologic testing between May 2020 and January 2021. We examined the crude associations of sociodemographic factors, epidemiologic risk factors, and county-level community transmission with the incidence of seroconversion. In multivariable Poisson models we examined the association of social distancing and a composite score of several epidemiologic risk factors with the rate of seroconversion.

# **Findings**

Among the 4,510 individuals with at least one serologic test, 323 (7.3%, 95% confidence interval [CI] 6.5%-8.1%) seroconverted by January 2021. Among 3,422 participants seronegative in May-September 2020 and tested during November 2020-January 2021, we observed 161 seroconversions over 1,646 person-years of follow-up (incidence rate of 9.8 per 100 person-years [95%CI 8.3-11.5]). In adjusted models, participants who reported always or sometimes social distancing with people they knew (IRR<sub>always vs. never</sub> 0.43, 95%CI 0.21-1.0; IRR<sub>sometimes vs. never</sub> 0.47, 95%CI 0.22-1.2) and people they did not know (IRR<sub>always vs. never</sub> 0.64, 95%CI 0.39-1.1; IRR<sub>sometimes vs. never</sub> 0.60, 95%CI 0.38-0.97) had lower rates of seroconversion. The rate of seroconversion increased across tertiles of the composite score of epidemiologic risk (IRR<sub>medium vs. low</sub> 1.5, 95%CI 0.92-2.4; IRR<sub>high vs. low</sub> 3.0, 95%CI 2.0-4.6). Among the 161 observed seroconversions, 28% reported no symptoms of COVID-like illness (i.e., were asymptomatic), and 27% reported a positive SARS-CoV-2 diagnostic test. Ultimately, only 29% reported isolating and 19% were asked about contacts.

#### Interpretation

Modifiable epidemiologic risk factors and poor reach of public health strategies drove SARS-CoV-2 transmission across the U.S during May 2020-January 2021.

#### Funding

U.S. National Institutes of Allergy and Infectious Diseases (NIAID).

## **INTRODUCTION**

A major challenge of controlling community transmission of SARS-CoV-2 is that the virus' infectious period allows for onward spread without, or prior to, diagnosis of infection[1,2], including by fully-vaccinated individuals.[3] One national study in the United States (U.S.) prior to the vaccine era estimated that there were 5 undiagnosed infections for every diagnosed case.[2]

While SARS-CoV-2 is understood to be transmitted from person-to-person via airborne and droplet spread, to date, the incidence of SARS-CoV-2 infection and risk factors for incident infection have not been adequately characterized by routine case-based surveillance of SARS-CoV-2 diagnoses or by cross-sectional seroprevalence studies.[4–6] It is critical for prospective studies to investigate COVID-19's evolving epidemiology and risk factors for SARS-CoV-2 acquisition in communities, including the uptake and impact of non-pharmaceutical interventions (NPIs)[7], and the reach of public health strategies aimed at controlling community transmission, including testing, quarantine, isolation, contact tracing, and vaccination.

Globally, few community-based prospective epidemiologic studies of SARS-CoV-2 incidence and risk factors have been undertaken. One recent global systematic review of observational studies of SARS-CoV-2 that employed serologic or polymerase chain reaction (PCR) testing found 18 prospective studies.[8] Most were focused on healthcare workers or other occupational groups, individuals in congregate settings, evacuees, or cruise ship patrons; none were community-based (i.e., focused on risk factors in communities vs other higher risk populations/settings).[8] Since then, there have been publications from a national community-based prospective cohort in the U.K. [9–11], but to date, there have been no prospective community-based studies with biomarkers in the U.S. Such studies are needed to help inform aspects of implementation of the public health response and policies, both to the current pandemic and future ones.

In late March 2020, we launched the prospective Communities, Households and SARS-CoV-2 Epidemiology (CHASING) COVID Cohort.[12] We describe the incidence of SARS-CoV-2 infection and risk factors for SARS-CoV-2 seroconversion during May 2020-January 2021, as well as the reach and uptake of public health strategies aimed at controlling community spread among those who seroconverted.

#### **METHODS**

#### Recruitment

We used internet-based strategies[13,14] to recruit a geographically and socio-demographically diverse cohort of adults into longitudinal follow-up with at-home specimen collection. To be eligible for inclusion in the cohort, individuals had to: 1) reside in the U.S. or a U.S. territory; 2) be ≥18 years old; 3) provide a valid email address for follow-up; and 4) demonstrate early engagement in study activities (provision of a baseline specimen or completion of >1 recruitment/enrollment visit). Details of the study design and recruitment procedures are described elsewhere.[15] The full cohort includes participants from all 50 U.S. states, the District of Columbia, Puerto Rico, and Guam (Supplemental Figure S1). Of the 6,738 participants in the full cohort, 4,510 (67%) had at least one serologic test and comprised the study population for this analysis (Table S1).

# **Data collection**

Cohort recruitment and enrollment visits were completed between March 28-August 21, 2020, during which multiple rounds of interviews took place. Demographic and COVID-19 related risk factors were collected at baseline. From three follow-up interviews between August and November 2020, we obtained repeated measurements of COVID-19 symptoms, laboratory testing (PCR or serologic), hospitalizations, use of NPIs such as mask use and social

distancing, public health strategies such as quarantine, isolation, and contact tracing encounters, and other time-varying factors.

During May-September 2020 (Period 1) and November 2020-January 2021 (Period 2), participants were invited to complete serologic testing using an at-home self-collected dried blood spot (DBS) specimen collection kit. DBS cards were sent from and returned to the study laboratory (Molecular Testing Laboratories [MTL], Vancouver, Washington) via the U.S. Postal Service using a self-addressed, stamped envelope containing a biohazard bag<sup>™</sup>.

All DBS specimens were tested by the study laboratory for total antibodies (Total Ab) using the Bio-Rad Platelia test for IgA, IgM, and IgG which targets the SARS-CoV-2 nucleocapsid protein (manufacturer sensitivity 98.0%, specificity 99.3%).[16] Other studies have independently validated this assay and found average sensitivity and specificity of 91.7% and 98.8%, respectively.[17–19] This assay was also validated for use with DBS by the study laboratory, which found 100% sensitivity and 100% specificity (MTL, personal communication).

#### **Outcomes**

Cumulative incidence of SARS-CoV-2 infection. Among participants who underwent serologic testing, we estimated the serology-based cumulative incidence of SARS-CoV-2 as the proportion of individuals with a positive Total Ab test in either of the two time periods (i.e., number of participants ever positive) divided by the total number of persons with one or more Total Ab tests (i.e., number of participants ever tested). We adjusted cumulative incidence estimates for laboratory test error, assuming a sensitivity of 91.7% and a specificity of 98.8%[17–19] using the following formula[20]:

 $Adjusted\ cumulative\ incidence = \frac{Crude\ cumulative\ incidence + Specificity - 1}{Sensitivity + Specificity - 1}$ 

Observed SARS-CoV-2 seroconversion. Among those individuals with two Total Ab tests, an observed seroconversion was defined as a negative Total Ab test in Period 1 followed by a positive Total Ab test in Period 2. We estimated person-years of follow-up using the collection dates for each specimen in Periods 1 and 2. When the collection date was missing, we used the date the laboratory received the sample. The seroconversion date was assigned as the midpoint between the first and second specimen collection dates for person-time calculations.

# **Exposures**

Individual-level COVID-19 risk factors. We examined epidemiologic risk factors for SARS-CoV-2 individually and as part of a composite score. We considered the following risk behaviors and factors reported by participants prior to specimen collection: Household factors (household crowding [4 or more people living in a household], having a child in the household, and having a confirmed COVID-19 case in a household member prior to participant testing positive), spending time in public places (attending mass gatherings such as protests, spending time in an indoor restaurant or bar, spending time at an outdoor restaurant or bar, visiting places of worship, or visiting public parks or pools), mask use indoors (for grocery shopping, visiting non-household members, at work, and in salons or gyms), mask use outdoors, gathering in groups with more than 10 people (indoors only, outdoors only, and indoors and outdoors), travel during the pandemic (recent air travel and public transit use), and individual-level factors that may increase the risk of severe COVID-19 (substance use, binge drinking, and medically diagnosed comorbidities).

Global social distancing assessment. While social distancing in specific scenarios is addressed in some of the above individual risk factors (such as spending time in various public places), we were specifically interested in the association between social distancing in general and incident SARS-CoV-2 infection. We asked two global questions on social distancing, which

were "In the past month, how often have you practiced social distancing with: a) people you know and b) people you do not know," with possible response options of Always, Sometimes, or Never. These assessments were not included in the calculation of the composite risk score.

Composite score of COVID-19 risk factors. We computed a composite COVID-19 risk score as many of the above COVID-19 risk factors may be highly correlated. We applied Least Absolute Shrinkage Selection Operator (LASSO) regression to select the set of risk factors which best predicted seroconversion.[21] Scores were assigned to each participant based on whether they engaged in the risk factors selected by the LASSO regression model and were normalized between 0 and 100. High scores indicate engagement in high-risk activities. Details are in the Statistical Appendix. The composite score was divided into tertiles (low, medium, high) for analysis.

# Statistical analysis

Cumulative incidence estimates were stratified by baseline characteristics and epidemiologic risk factors. Crude and adjusted Incidence Rate Ratios (IRRs) of seroincidence and associated 95% confidence intervals (CIs) were estimated using Poisson regression. We examined crude seroconversion rates by sociodemographic characteristics and each risk factor. Finally, we separately modeled three exposure variables: 1) social distancing with "people you know" (Yes/No); 2) social distancing with "people you don't know" (Yes/No); and 3) the composite COVID-19 risk score(high/medium/low). Two multivariable models were constructed for each exposure variable, including models that adjusted for age, gender, race/ethnicity and comorbidities (Model 1); and a model that further controlled for changes in community-level COVID-19 transmission (Model 2). See Statistical Appendix for details. All data were cleaned and analyzed in R (version 4.0.3) and SAS (V9.4).

# **Ethical Approval**

The study protocol was approved by the Institutional Review Board at the City University of New York (CUNY).

#### RESULTS

#### Sample characteristics

The characteristics of the study sample are shown in Table 1. A total of 4,232 persons underwent serologic testing in Period 1, and 3,883 were tested in Period 2 (Table S1). Of the 4,510 participants who tested at least once, 3,605 (80%) tested at both time points (Table 1). Differences between those participants testing in Period 1 and Period 2 were negligible (<u>Table S1</u>). The median time between specimen collection dates for participants providing specimens for both serologic tests was 190 days (IQR 152-201) (Figure S2).

# Cumulative incidence of SARS-CoV-2 as of January 31, 2021

We observed 323 seropositives among the 4,510 participants who tested at least once during follow-up, for an overall crude and adjusted serology-based estimates of cumulative incidence of 7.3% (95% confidence interval [CI]: 6.5%-8.1%) and 6.7% (95% CI 5.9%-7.6%), respectively (Table S2).

# SARS-CoV-2 seroincidence, May 2020-January 2021

There were 3,422 participants who were seronegative in Period 1 with a subsequent serologic test in Period 2 who were followed prospectively for the outcome of SARS-CoV-2 seroconversion. There were 161 observed seroconversions over 1,646 person years of follow-up, for an overall incidence rate of 9.8 per 100 person-years (95% CI 8.3-11.5) (Table 2). The rate of incident SARS-CoV-2 infection was lower for females compared to males (IRR=0.69, 95% CI:0.50, 0.94), and higher for Hispanics (IRR=2.09, 95% CI 1.41-3.05) and non-Hispanic

Blacks (IRR=1.69, 95% CI 0.96-2.82) compared with non-Hispanic Whites. Essential workers had higher incidence than non-essential workers (IRR=1.65, 95% CI 1.10-2.26). Incidence rates were higher among those in rural versus urban areas (IRR=1.29, 95% CI 0.89-1.29), and among those in the Midwest (IRR=1.59, 95% CI 0.98-2.56), the South (IRR=1.67, 95% CI 1.08-2.59), and the West (IRR=1.32, 95% CI 0.83-2.11) compared to the Northeast.

Table 3 shows the seroincidence and crude incidence rate ratios by epidemiologic risk factors that were present prior to or between serologic tests. There was higher incidence among those who dined indoors at restaurants or bars (IRR=1.93, 95% CI 1.39-2.70); those who visited a place of worship (IRR=1.92, 95% CI 1.26-2.84); those who wore a mask only sometimes while grocery shopping (IRR=10.57, 95% CI 4.00-30.51); those who visited indoors with people not in their own household while sometimes wearing a mask (IRR=1.94; 95% CI 1.37-3.31) or while never wearing a mask (IRR=2.62; 95% CI 1.50-4.70); those working indoors at a place of employment while never wearing a mask (IRR=2.50, 95% CI 0.98-5.26); those who wore masks only sometimes while attending a salon or gym (IRR=3.23, 95% CI 1.90-5.23); and those who reported traveling by air during August-November 2020 (IRR=1.52, 95% CI 1.05-2.17).

# Poisson models of SARS-CoV-2 seroconversion for three different exposures of interest, May 2020-January 2021

Global social distancing assessment. In crude analyses, participants who reported that they always or sometimes engaged in social distancing with people they know had a statistically significantly lower seroincidence (IRR<sub>always vs never</sub>=0.30, 95% CI 0.15-0.72; IRR<sub>sometimes vs</sub> never=0.35, 95% CI 0.16-0.86) compared with those who said they never social distanced with people they know (Table 4). In multivariable analyses that controlled for sociodemographics and comorbidities (Model 1, aIRR<sub>always vs never</sub>=0.37, 95% CI: 0.18-0.89), and additionally for community-level transmission (Model 2, aIRR<sub>always vs never</sub>=0.43, 95% CI: 0.21-1.04), participants who reported always social distancing with those they know (versus never) had a significantly

lower seroincidence, although the 95% confidence intervals were wider. Participants reporting that they socially distanced *sometimes* with people they knew also had lower incidence of seroconversion compared with those never socially distancing in both models (Table 4).

Participants who reported social distancing *always* or *sometimes* (*vs. never*) with people they don't know had lower seroincidence rates in both crude analyses and adjusted models, however the association was weaker than it was for social distancing with people they *did* know, with IRRs and aIRRs ranging from 0.53-0.64.

Clinical and public health outcomes among persons with SARS-CoV-2 seroconversion during May 2020-January 2021

Among the 161 individuals who seroconverted during May 2020-January 2021, only 27 (16.8%) were aware that they had a prior SARS-CoV-2 infection (Table 5). A substantial proportion (28.0%) recalled no symptoms of COVID-like illness (i.e., were asymptomatic cases). In terms of public health outcomes, 60.3% said that they were ever tested for SARS-CoV-2 outside the study (Table 5), but only half of them (26.7% of total) reported ever having a positive SARS-CoV-2 test. Only 29.2% said that they had *ever* isolated themselves from people outside their household because of their infection, and, among those who did not live alone, even fewer (17.4% overall) said they ever isolated themselves from others within their household. In terms of contact tracing, only 19.3% of all seroconverters were asked about contacts following diagnosis and only 11.8% had been informed by a contact tracer that they may have had contact with someone confirmed to have SARS-CoV-2. Only 5.0% of all seroconverters were told by a contact tracer to stay home for a period of time because they had COVID-19. Findings were similar among all 323 seropositive participants (data not shown).

## **DISCUSSION**

We report findings from a large community-based prospective epidemiologic study of SARS-CoV-2 incidence and risk factors in the U.S. during May 2020-January 2021. Using serologic tests, we longitudinally characterized the incidence of SARS-CoV-2 infection in relation to a range of modifiable risk factors. We found that social distancing with those whom participants knew as well as those whom they did not know was highly protective against SARS-CoV-2 infection, even after controlling for other risk factors and measured confounders. Finally, public health strategies such as quarantining, testing, isolation, and contact tracing appear to have had inadequate coverage and adoption during the infectious periods of those infected with SARS-CoV-2, limiting their effectiveness at reducing SARS-CoV-2 transmission in the community. Taken together, our study findings document some of the principal reasons why the U.S. has continued to experience sustained community transmission, hospitalizations, and deaths from COVID-19 in many areas, including into the vaccine and Delta variant eras.

The protective association observed for two global measures of social distancing persisted even after controlling for other differences. This protective association was strongest for participants reporting that they always or sometimes socially distanced from people whom they knew, but was also present among those who always or sometimes socially distanced from those they did not know. Our findings suggest a need for more effective and consistent messaging around social distancing.

We observed substantially increased risk, in dose response fashion, from a number of other key epidemiologic risk factors and exposures reflected in a composite risk score. Among participants in the top tertile of the risk score the risk of seroincidence was 3-fold higher, accounting for 55% of the observed seroconversions. Reducing multiple risk factors (e.g., through policies on masking, mass gatherings, indoor dining/bars, social distancing, air travel) would likely substantially reduce community transmission.

Our findings suggest that elevated risk among essential workers, observed early in the U.S. pandemic, persisted into the second phase of the pandemic. Essential workers risk exposure to SARS-CoV-2 not only in their workplaces, but also in their communities and as part of their commutes to and from work, especially when using public transportation. The increased burden of risk of SARS-CoV-2 infection in essential workers is shared with their household members, among whom transmission is very efficient.[28] National, state and local workplace safety measures, mandates, and policies that protect essential workers have the added benefit of protecting household members and other close contacts of workers.

Finally, detailed examination of 161 individuals with SARS-CoV-2 seroconversion showed major gaps in the reach of public health interventions aimed at reducing the spread of SARS-CoV-2. Most who seroconverted (73.3%) did not report a prior positive PCR test, and a substantial proportion were asymptomatic. Moreover, few people who seroconverted in our study reported being reached by contact tracers (11.8%). These results highlight the barriers to successful implementation of isolation, contact tracing, and quarantine. Now that rapid home tests are easily available, frequent proactive testing at home can be a more effective way to capture asymptomatic and presymptomatic cases early and prevent onward transmission.

Our study, as well as data from routine case surveillance, highlight that the drivers of racial/ethnic disparities in SARS-CoV-2 risk have not been addressed in the U.S. The ultimate drivers of these disparities need to be targeted by governments, health departments and researchers, and used to course-correct the public health response.[29] Structural factors, such as household crowding, the need to go to work to avoid income loss, and inequitable access to SARS-CoV-2 testing[30], create and perpetuate a disparate burden of SARS-CoV-2 exposure and incidence.[31] To date, no targeted strategies or policies have been deployed that aim to protect those who cannot afford missing work, including, but not only, essential workers. Public health leaders and policy makers should anticipate and proactively design pandemic response implementation strategies, with performance metrics related to inequalities[32,33], that account

for and counteract the prevailing structural forces, including structural racism, that create, maintain, or exacerbate inequities in safety, health, and well-being during and after a public health crisis.[32–35]

Our study has limitations worth noting. The observed cumulative incidence in our cohort may be lower than the true cumulative incidence in our cohort because of waning of SARS-CoV-2 antibodies.[36] Recent studies suggest waning of antibodies to both nucleocapsid and spike proteins.[5] Combined with the timing of specimen collection relative to infection for many participants in our cohort (median of 190 days)[12], this could mean that we have underestimated the true cumulative incidence. Next, estimated associations between SARS-CoV-2 risk factors and incidence are subject to confounding. The crude associations we presented may also vary by setting, with interpretation for some associations further hampered by small sample sizes. Some risk behaviors may have been underreported, due to social desirability, which would bias observed associations toward the null. Finally, our study period for the current analysis pre-dated the vaccine era and the emergence of the highly transmissible and possibly more virulent SARS-CoV-2 Delta variant. We could not, therefore, examine risk factors for infection among vaccinated persons. However, given recent data showing decreasing vaccine effectiveness against the Delta variant for the outcome of infection[37,38], as well as major outbreaks and high viral loads among fully vaccinated persons[3,39], it is likely that many of our findings related to transmission risk factors also apply to vaccinated persons, as they remain at risk for breakthrough infection and onward transmission of SARS-CoV-2 when engaging in some of the same risk factors. A similar study performed in the Delta variant era might result in stronger risk factor and weaker protective factor associations with seroconversion, as well as a different estimate of proportion asymptomatic.

Conclusion

Modifiable risk factors and poor reach of public health strategies continue to drive transmission of SARS-CoV-2 across the U.S. While continuing to increase vaccine access and coverage, it remains critical for public health agencies to simultaneously reduce risk factors and address structural factors that contribute to high incidence and persistent inequities. Future research will include monitoring SARS-CoV-2 outcomes, including infections in the vaccine and Delta variant eras, at least through December 2021.

**CONTRIBUTORS** 

DN, MSR, SGK, MMR, conceptualized the study. MSR, MC and DN performed statistical analyses. DN and MSR wrote the first draft of the paper. DN, MSR, MC, SGK, and AP contributed to interpreting the data, DN, RZ, MSR, MC, SGK, WY, AB, CM, SK, AM, MMR, DAW, AP, LW, and CG contributed to the writing and revising of the manuscript. SGK, WY, AB, CM, SK, and DN contributed to data collection, cleaning and management. DN, SGK, MMR and CG contributed to obtaining funding for the research.

**ACKNOWLEDGEMENTS** 

The authors wish to thank the participants of the CHASING COVID Cohort Study. We are grateful to you for your contributions to the advancement of science around the SARS-CoV-2 pandemic. We thank Prof. Patrick Sullivan and MTL for local validation work on the serologic assays for use with DBS that greatly benefited our study. We are also grateful to MTL Labs for processing specimen collection kits and serologic testing of our cohort's specimens.

# **FUNDING**

Funding for this project is provided by The National Institute of Allergy and Infectious Diseases (NIAID), award number 3UH3AI133675-04S1 (MPIs: D Nash and C Grov), the CUNY Institute for Implementation Science in Population Health (cunyisph.org) and the COVID-19 Grant Program of the CUNY Graduate School of Public Health and Health Policy, and National Institute of Child Health and Human Development grant P2C HD050924 (Carolina Population Center).

#### STATISTICAL APPENDIX

LASSO. The study sample of 3,422 participants with 2 serosamples was split randomly into equally sized training and test data sets. A grouped LASSO regression was fit using training data and 10-fold cross validation was used to obtain the minimum value of lambda (the tuning parameter). The variables included in the LASSO model were household crowding, having children in the household, confirmed COVID-19 case in a household member, attending mass gatherings, indoor dining in a restaurant/bar, outdoor dining in a restaurant/bar, visiting places of worship, visiting public park or pool, gathering with groups of 10 or more indoors and/or outdoors, mask use while grocery shopping, mask use while visiting non-household members, mask use indoors in gym/salons, mask use indoors at work, mask use outdoors, using public transit, recent air travel, alcohol use, and substance use. Using the minimum lambda value, a grouped LASSO model was run on the entire dataset (training + test) to obtain factors that best predicted seroconversion. The LASSO model selected having a confirmed COVID-19 case in a household member, indoor dining in a bar/restaurant, gathering with groups of 10 or more outdoors, and mask use indoors in salons/gyms as the most predictive of seroconversion in our cohort. A logistic regression model was fitted using these variables selected by LASSO regression with seroconversion (Y/N) as the outcome. Coefficients of the variables were multiplied by 10 and rounded up to the nearest integer to create a score associated with that variable/risk factor. If a participant engaged in a given risk factor, they were assigned the score associated with that risk factor. Scores were then summed across risk factors, normalized between 0 and 100, and a total composite risk score was created for each participant.

County-level COVID-19 community transmission. We used population-based, county-level death rates, lagged by 23 days [22,23], as a proxy for community transmission. We assumed that data on the number of deaths for a given day represented community transmission that was occurring 23 days earlier, specifically 5 days from infection to symptom onset (reflecting the

average incubation period) [24]; 5 days from symptom onset to severe disease/hospitalization [25]; and 13 days from hospitalization to death. [26]

We obtained the cumulative number of COVID-19 deaths per 100,000 persons for each county, using data from the New York Times Github website (from 01/21/2020 to 01/07/2021)[27] on the days samples were collected in Period 1 and Period 2 for each participant. We calculated the rate of change in cumulative COVID-19 deaths per 100,000 at three time points for each participant, including between: 1) January 2020 (approximate start of U.S. pandemic) and the date of specimen collection in Period 1; 2) the start of the pandemic and the date of specimen collection in Period 2; and 3) the difference between the specimen collection dates in Period 1 and Period 2. The rate of change in COVID-19 deaths per 100,000 were divided into tertiles of low, medium and high community transmission.

# **TABLES AND FIGURES**

Table 1. Baseline characteristics of CHASING COVID Cohort Study participants who provided a dried blood spot sample for antibody testing

who provided a dried blood spot same	Participants with c serologic to	
	N	%
Total	4,510	100.00
Two serologic tests	3,605	79.93
Age		
Median (IQR)	41 (31, 55)	
18-29	876	19.42
30-39	1,253	27.78
40-49	858	19.02
50-59	658	14.59
60+	865	19.18
Gender		
Male	2,018	44.75
Female	2,360	52.33
Non-Binary/Transgender	132	2.93
Race/Ethnicity		
Non-Hispanic White	2,966	65.76
Hispanic	679	15.06
Non-Hispanic Black	378	8.38
Asian/PI	304	6.74
Other	168	3.73
Missing	15	0.33
Education	. •	0.00
Less than high school	54	1.20
High school graduate	403	8.94
Some college	1,151	25.52
College graduate	2,902	64.35
Employment	_,00_	000
Employed	2,774	61.51
Out of work	544	12.06
Homemaker	242	5.37
Student	367	8.14
Retired	583	12.93
Household income	333	12.00
Less than \$35,000	1,186	26.30
\$35-49,999	496	11.00
\$50-69,999	643	14.26
\$70-99,999	741	16.43
\$100,000+	1,329	29.47
Don't know	112	2.48
Missing	3	0.07
Setting	5	0.07
Urban	1,911	42.37
Suburban	1,186	26.30
Guburbari	1,100	20.50

Rural	1,412	31.31
Missing	1	0.02
Geographic region		
Northeast	1,320	29.27
Midwest	805	17.85
South	1,269	28.14
West	1,111	24.63
US Territories	5	0.11
Healthcare worker		
No	4,048	89.76
Yes	425	9.42
Don't know	37	0.82
Essential worker *		
No	3,170	70.29
Yes	1,340	29.71
Higher risk for severe COVID **		
No	2,097	46.50
Yes	2,413	53.50

<sup>\*</sup> Combined from three follow-up interviews between August and November 2020

<sup>\*\* &</sup>gt;60 years old, or reported co-morbidity, or current smoker. Comorbidity was defined as having history of heart attack, depression, angina, immunosuppression, type 2 diabetes, high blood pressure, cancer, asthma, COPD, chronic kidney disease, and/or HIV/AIDS

medRxiv preprint doi: https://doi.org/10.1101/2021.02.12.21251659; this version posted October 12, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.

Table 2: Crude associations of COVID-19 sociodemographic factors with seroincidence, May 2020-January 2021

	No. of seronegative participants in Period 1 *	No. of incident infections in Period 2 **	Total person- years of follow up	Seroincidence per 100 person-years	Rate Ratio (95% CI)
Total	3,422	161	1,646.04	9.8 (8.3, 11.5)	· · · ·
Age group					
18-29	617	37	300.00	12.33 (8.9, 16.7)	(ref)
30-39	934	46	449.00	10.24 (7.6, 13.5)	0.83 (0.53, 1.28)
40-49	654	33	310.00	10.65 (7.5, 14.7)	0.86 (0.53, 1.38)
50-59	514	23	249.00	9.24 (6.1, 13.7)	0.74 (0.43, 1.25)
60+	703	22	339.00	6.49 (4.2, 9.8)	0.52 (0.30, 0.88)
Gender				,	,
Male	1,516	88	748.00	11.76 (9.6, 14.3)	(ref)
Female	1,810	69	850.00	8.12 (6.4, 10.2)	0.69 (0.50, 0.94)
Non-Binary/Transgender	96	4	48.71	8.21 (2.6, 20.6)	0.69 (0.21, 1.73)
Race/Ethnicity				,	,
Non-Hispanic White	2,307	92	1,141.00	8.06 (6.5, 9.8)	(ref)
Hispanic	500	37	219.00	16.89 (12.3, 22.6)	2.09 (1.41, 3.05)
Non-Hispanic Black	261	16	117.00	13.68 (8.2, 21.5)	1.69 (0.96, 2.82)
Asian/PI	222	7	106.78	6.56 (2.9, 13.5)	0.81 (0.34, 1.66)
Other	132	9	63.02	14.28 (7.1, 25.9)	1.77 (0.84, 2.77)
Education				,	
Less than high school	37	2	16.10	12.42 (2.1, 39.4)	(ref)
High school graduate	278	14	121.00	11.57 (6.7, 18.9)	0.93 (0.24, 6.05)
Some college	815	44	377.00	11.67 (8.7, 15.4)	0.93 (0.27, 5.76)
College graduate	2,292	101	1,132.00	8.92 (7.3, 10.8)	0.71 (0.21, 4.33)
Employment				,	
Employed	2,102	109	1,020.00	10.69 (8.8, 12.8)	(ref)
Out of work	402	18	188.90	9.53 (5.9, 14.9)	0.89 (0.52, 1.44)
Homemaker	179	7	78.70	8.89 (3.9, 18)	0.86 (0.35, 1.68)
Student	253	12	126.00	9.52 (5.2, 16.4)	0.89 (0.46, 1.57)
Retired	486	15	233.00	6.44 (3.7, 10.6)	0.60 (0.33, 1.01)
Household income				,	,
Less than \$35,000	880	43	405.00	10.62 (7.8, 14.1)	(ref)

\$35-49,999	383	23	182.00	12.64 (8.3, 18.5)	1.19 (0.70, 1.96)
\$50-69,999	505	18	241.00	7.47 (4.6, 11.7)	0.70 (0.39, 1.20)
\$70-99,999	592	34	286.00	11.89 (8.4, 16.3)	1.12 (0.70, 1.75)
\$100,000+	993	38	495.00	7.68 (5.5, 10.5)	0.72 (0.46, 1.12)
Don't know	77	5	37.00	13.5 (5.1, 29.5)	1.27 (0.44, 3.01)
Missing	2				
Setting					
Urban	1,442	62	707.00	8.7 (6.8, 11.1)	(ref)
Suburban	904	42	438.00	9.58 (7.1, 12.8)	1.11 (0.74, 1.65)
Rural	1,076	57	501.00	11.37 (8.8, 14.6)	1.29 (0.89, 1.29)
Geographic region					
Northeast	977	34	477.00	7.13 (5, 9.9)	(ref)
Midwest	629	34	300.00	11.33 (8.1, 15.6)	1.59 (0.98, 2.56)
South	953	53	445.00	11.91 (9.1, 15.3)	1.67 (1.08, 2.59)
West	859	39	413.00	9.44 (6.9, 12.8)	1.32 (0.83, 2.11)
US Territories	4				
Healthcare worker					
No	3,074	140	1,481.00	9.45 (8, 11.1)	(ref)
Yes	315	19	150.00	12.67 (7.9, 19.3)	1.34 (0.80, 2.12)
Don't know	33	2	14.00	14.3 (2.5, 43.8)	1.51 (0.25, 5.07)
Essential worker ***					
No	2,407	95	1,160.00	8.1 (6.7, 9.9)	(ref)
Yes	1,015	66	486.00	13.6 (10.7, 17.0)	1.65 (1.10, 2.26)
High Risk group ****					
No	1,574	83	761.00	10.91 (8.8, 13.4)	(ref)
Yes	1,848	78	885.00	8.81 (7.1, 10.9)	0.80 (0.59, 1.10)

<sup>\*</sup> May - September 2020

<sup>\*\*</sup> November 2020 - January 2021

<sup>\*\*\*</sup> Combined from three follow-up interviews between August and November 2020
\*\*\*\* >60 years old, or reported co-morbidity, or current smoker. Comorbidity was defined as having history of heart attack, depression, angina, immunosuppression, type 2 diabetes, high blood pressure, cancer, asthma, COPD, chronic kidney disease, and/or HIV/AIDS

medRxiv preprint doi: https://doi.org/10.1101/2021.02.12.21251659; this version posted October 12, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.

Table 3: Crude associations of COVID-19 risk factors with seroincidence, May 2020-January 2021

	No. of seronegative participants in Period 1 *	No. of incident infections in Period 2 **	Total person- years of follow up	Incidence rate per 100 person-years (95% CI)	Rate Ratio (95% CI)
Total	3,422	161	1,646.04	9.8 (8.3, 11.5)	
Household factors					
Household crowding	822	43	378.88	11.4 (8.3, 15.4)	1.21 (0.85, 1.71)
No household crowding	2,600	118	1,267.16	9.3 (7.7, 11.2)	ref
Child in household	653	28	296.07	9.5 (6.5, 13.8)	0.95 (0.62, 1.42)
No child in household	2,769	133	1,349.97	9.9 (8.3, 11.7)	ref
Confirmed case in household member	23	12	102.28^	11.7 (5.2, 26.6)	15.7 (8.71, 28.27)
No confirmed case in household member	3,399	149	19,938.30^	0.7 (0.6, 0.9)	ref
Social distancing					
Social distancing with people you know					
Always	2,616	113	1,258.00	8.9 (7.4, 10.7)	0.29 (0.14, 0.69)
Sometimes	660	34	319.00	10.6 (7.6, 14.7)	0.35 (0.16, 0.86)
Never	53	7	23.30	30.0 (13.8, 52.4)	ref
Not Applicable	53	4	24.50	16.3 (5.3, 37.5)	0.53 (0.13, 1.83)
Social distancing with people you do not know				, ,	,
Always	1,137	51	543.00	9.4 (7.1, 12.2)	0.54 (0.33, 0.89)
Sometimes	1,787	79	868.00	9.1 (7.3, 11.3)	0.52 (0.33, 0.84)
Never	300	24	139.00	17.3 (11.5, 24.8)	ref
Not Applicable	158	4	74.50	5.4 (1.7, 13.9)	0.31 (0.09, 0.83)
Spent time in public places					
Attended mass gathering(s)	350	18	174.89	10.3 (6.4, 16.5)	1.05 (0.63, 1.69)
Did not attend mass gathering(s)	3,072	143	1,471.15	9.7 (8.2, 11.5)	ref
Indoor dining/bar	1,755	108	843.86	12.8 (10.5, 15.5)	1.93 (1.39, 2.70)
No indoor dining/bar	1,667	53	802.18	6.6 (5.0, 8.7)	ref

Outdoor dining/bar No outdoor dining/bar	1,869 1,553	97 64	924.35 721.70	10.5 (8.6, 12.9) 8.9 (6.9, 11.4)	1.18 (0.63, 1.62) ref
Visited place of worship Did not visit place of worship	359 3,063	29 132	168.87 1,477.17	17.2 (11.7, 25.1) 8.9 (7.5, 10.6)	1.92 (1.26, 2.84) ref
Visited public park/public pool Did not visit public park/pool	2,189 1,233	100 61	1,076.41 569.63	9.3 (7.6, 11.4) 10.7 (8.3, 13.9)	0.86 (0.63, 1.19) ref
Gathered in groups ≥10					
No .	126	6	63.11	9.5 (4.2, 21.6)	ref
Indoors only	231	11	109.34	10.1 (5.5, 18.4)	1.06 (0.39,3.09)
Outdoors only	647	38	318.32	11.9 (8.6, 16.6)	1.26 (0.55, 3.26)
Indoors and outdoors	2,418	106	1,155.28	9.2 (7.6, 11.1)	0.96 (0.45, 2.42)
Mask Use					
Mask while grocery shopping					
Did not go grocery shopping	133	6	63.43	9.5 (4.2, 21.5)	ref
Always	3,084	140	1,489.12	9.4 (7.9, 11.1)	0.99 (0.46, 2.99)
Sometimes	132	12	57.22	21.0 (11.6, 38.0)	10.57 (4.00, 30.51)
Never	33	0	15.11	0	0 (0, 2.71)
Mask while indoors visiting non-household members N/A (Did no visit non-household members					
indoors)	669	19	319.92	5.9 (3.8, 9.4)	ref
Always	1,118	43	546.26	7.9 (5.8, 10.7)	1.32 (0.77, 2.32)
Sometimes	1,131	63	546.44	11.5 (8.9, 14.9)	1.94 (1.37, 3.31)
Never	463	33	211.58	15.6 (10.9, 22.22)	2.62 (1.5, 4.7)
Mask while indoors at work					
N/A (Did not attend indoor workplace)	1,642	63	789.46	8.0 (6.2, 10.3)	ref
Always	1,372	71	660.60	10.7 (8.5, 13.6)	1.34 (0.95, 1.89)
Sometimes	299	18	144.08	12.5 (7.8, 20.1)	1.56 (0.90, 2.60)
Never	68	6	30.05	20.0 (8.6, 46.2)	2.50 (0.98, 5.26)
Mask while at salon/gym					
N/A (Did not attend salon/gym)	1,567	56	749.79	7.5 (5.7, 9.8)	ref
Always	1,527	75	743.45	10.1 (8.0, 12.7)	1.31 (0.95, 1.91)

Sometimes	180	20	82.69	24.2 (15.2, 38.5)	3.23 (1.90, 5.23)
Never	108	7	48.94	14.3 (6.6, 30.8)	1.91 (0.80, 4.01)
Outdoor mask use					
Mask use outdoors	1,562	67	753.27	8.9 (7.0, 11.4)	0.84 (0.67, 1.15)
No mask use outdoors	1,860	94	892.78	10.5 (8.6, 13.0)	ref
Movement during the pandemic					
Use of public transit					
Avoided or did not use	2,975	138	1,434.70	9.6 (8.1, 11.4)	0.88 (0.57, 1.40)
Used public transit	447	23	211.35	10.9 (7.2, 16.6)	ref
Recent air travel (August – November 2020)					
Yes	582	39	287.91	13.5 (9.8, 18.7)	1.52 (1.05, 2.17)
No	2,800	119	1,336.97	8.9 (7.4, 10.7)	ref
Missing	40	3	21.17	14.2 (4.4, 46.0)	
Other potential risk factors					
Alcohol use ***	523	37	249.28	14.8 (10.6, 20.7)	1.67 (1.14, 2.39)
Substance use ****	914	45	443.40	10.1 (7.5, 13.7)	1.05 (0.73, 1.47)
Any comorbidities ^^	1,490	69	714.52	9.7 (7.6, 12.3)	0.97 (0.71, 1.33)
Changes in county-level community transmission					
High (0.327-3.30)	1,139	76	536.00	14.2 (11.4, 17.5)	ref
Medium (0.211-0.327)	1,140	37	557.00	6.6 (4.8, 9.1)	0.46 (0.31, 0.69)
Low (0-0.211)	1,139	48	550.00	8.7 (6.5, 11.4)	0.61 (0.42, 0.88)
Missing	4		1.00	·	

<sup>\*</sup> May - September 2020

<sup>\*\*</sup> November 2020 - January 2021

<sup>\*\*\*</sup> Having more than 6 alcoholic drinks on one occasion in last month

<sup>\*\*\*\*</sup> Used prescription opioids, street opioids, or cannabis in last month

<sup>^</sup> Person-time is in person-months

<sup>^ &</sup>gt;60 years old, or reported co-morbidity, or current smoker. Comorbidity was defined as having history of heart attack, depression, angina, immunosuppression, type 2 diabetes, high blood pressure, cancer, asthma, COPD, chronic kidney disease, and/or HIV/AIDS

medRxiv preprint doi: https://doi.org/10.1101/2021.02.12.21251659; this version posted October 12, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.

Table 4: Crude and adjusted\* incidence rate ratios (IRRs) for seroincidence in the CHASING COVID Cohort Study, May 2020-January 2021

	Crude		-	usted el 1 **)	•	sted el 2 ***)
	IRR	95% CI	IRR	95% CI	IRR	95% CI
Social distancing with people you know (ref:Never)						
Always	0.30	0.15, 0.72	0.37	0.18, 0.89	0.43	0.21, 1.04
Sometimes	0.35	0.16, 0.86	0.42	0.19, 1.05	0.47	0.22, 1.19
Not applicable (as per participant)	0.54	0.14, 1.80	0.70	0.18, 2.36	0.73	0.19, 2.48
Social distancing with people you do not know (ref:Never)						
Always	0.54	0.34, 0.90	0.60	0.37,1.00	0.64	0.39, 1.07
Sometimes	0.53	0.34, 0.85	0.57	0.37, 0.92	0.60	0.38, 0.97
Not applicable (as per participant)	0.30	0.09, 0.78	0.34	0.10, 0.89	0.36	0.10, 0.95
Composite measure of risk factors (ref:Low)						
Medium	1.54	0.97, 2.51	1.61	1.00, 2.64	1.59	0.99, 2.60
High	3.18	2.11, 4.95	3.17	2.07, 5.00	3.12	2.04, 4.93

<sup>\*</sup> Adjusted for test sensitivity and specificity

<sup>\*\*</sup> Model 1: Adjusted for age, gender, race/ethnicity, and comorbidities

<sup>\*\*\*</sup> Model 2: Adjusted additionally for county-level changes in community level transmission

Table 5. Clinical and public health outcomes among persons with seroincident SARS-CoV-2, May 2020-January 2021

ividy 2020 dandary 2021	N	%
Total	161	50%
Symptoms and clinical outcomes		
PCR confirmed diagnosis	43	26.7
Asymptomatic *	45	28
Mild (symptomatic, but didn't seek care)	99	61.5
Ever had COVID like illness*	114	70.8
Nasal discharge, congestion or sneezing	100	62.1
Cough/Cough up phlegm	75	46.6
Cough up blood	0	0
Sore throat	65	40.4
Itchy eye or eye pain	53	32.9
Shortness of breath or chest pain	32	19.9
Stomachache, diarrhea, nausea or vomiting	67	41.6
Rash	12	7.5
Loss of smell	31	19.3
Headache	89	55.3
Fever, chills or repeated chills	44	27.3
Myalgia	58	36
Ever hospitalized	4	2.5
Public health outcomes and testing history		
Ever tested for COVID	97	60.3
Positive SARS-CoV-2 PCR test	43	26.7
Isolated from people outside household	47	29.2
Isolated from people within household **	28	17.4
Quarantined after contact with COVID	31	19.3
Asked about contacts after COVID diagnosis	31	19.3
Told about contacts with COVID case	19	11.8
Encouraged to get tested because of exposure to case	10	6.2
Told to stay home for a period of time	8	5

<sup>\*</sup> Based on Council of State and Territorial Epidemiologists case definition

<sup>\*\*</sup> Among those with others in the household

#### REFERENCES

- Buitrago-Garcia D, Egli-Gany D, Counotte MJ, et al. Occurrence and transmission potential
  of asymptomatic and presymptomatic SARS-CoV-2 infections: A living systematic review
  and meta-analysis. PLoS Med 2020; 17:e1003346.
- Kalish H, Klumpp-Thomas C, Hunsberger S, et al. Mapping a Pandemic: SARS-CoV-2 Seropositivity in the United States. medRxiv 2021; Available at: http://dx.doi.org/10.1101/2021.01.27.21250570.
- 3. Brown CM, Vostok J, Johnson H, et al. Outbreak of SARS-CoV-2 Infections, Including COVID-19 Vaccine Breakthrough Infections, Associated with Large Public Gatherings Barnstable County, Massachusetts, July 2021. MMWR. Morbidity and Mortality Weekly Report. 2021; 70:1059–1062. Available at: http://dx.doi.org/10.15585/mmwr.mm7031e2.
- 4. Angulo FJ, Finelli L, Swerdlow DL. Estimation of US SARS-CoV-2 Infections, Symptomatic Infections, Hospitalizations, and Deaths Using Seroprevalence Surveys. JAMA Netw Open **2021**; 4:e2033706.
- Bajema KL, Wiegand RE, Cuffe K, et al. Estimated SARS-CoV-2 Seroprevalence in the US as of September 2020. JAMA Intern Med 2020; Available at: http://dx.doi.org/10.1001/jamainternmed.2020.7976.
- CDC. COVID Data Tracker. 2020. Available at: https://covid.cdc.gov/covid-data-tracker/. Accessed 31 January 2021.
- 7. Hutchins HJ, Wolff B, Leeb R, et al. COVID-19 Mitigation Behaviors by Age Group United States, April-June 2020. MMWR Morb Mortal Wkly Rep **2020**; 69:1584–1590.
- 8. Oran DP, Topol EJ. The Proportion of SARS-CoV-2 Infections That Are Asymptomatic: A Systematic Review. Ann Intern Med **2021**; Available at: http://dx.doi.org/10.7326/M20-6976.
- 9. Pouwels KB, House T, Pritchard E, et al. Community prevalence of SARS-CoV-2 in England from April to November, 2020: results from the ONS Coronavirus Infection Survey. Lancet Public Health **2021**; 6:e30–e38.
- 10. Wei J, Stoesser N, Matthews PC, et al. Antibody responses to SARS-CoV-2 vaccines in 45,965 adults from the general population of the United Kingdom. Nat Microbiol **2021**; Available at: http://dx.doi.org/10.1038/s41564-021-00947-3.
- 11. COVID-19 INFECTION SURVEY. Available at: https://www.ndm.ox.ac.uk/covid-19/covid-19-infection-survey. Accessed 1 August 2021.
- Robertson M, Kulkarni S, Berry A, et al. A national prospective cohort study of SARS/COV2 pandemic outcomes in the U.S.: The CHASING COVID Cohort. Infectious Diseases (except HIV/AIDS). 2020; Available at: https://www.medrxiv.org/content/10.1101/2020.04.28.20080630v1.
- 13. Nash D, Stief M, MacCrate C, et al. A Web-Based Study of HIV Prevention in the Era of Pre-Exposure Prophylaxis Among Vulnerable HIV-Negative Gay and Bisexual Men, Transmen, and Transwomen Who Have Sex With Men: Protocol for an Observational

- Cohort Study. JMIR Research Protocols. 2019; 8:e13715. Available at: http://dx.doi.org/10.2196/13715.
- 14. Grov C, Westmoreland D, Rendina HJ, Nash D. Seeing Is Believing? Unique Capabilities of Internet-Only Studies as a Tool for Implementation Research on HIV Prevention for Men Who Have Sex With Men: A Review of Studies and Methodological Considerations. J Acquir Immune Defic Syndr 2019; 82 Suppl 3:S253–S260.
- 15. Robertson MM, Kulkarni SG, Rane M, et al. Cohort profile: a national, community-based prospective cohort study of SARS-CoV-2 pandemic outcomes in the USA-the CHASING COVID Cohort study. BMJ Open **2021**; 11:e048778.
- Center for Devices, Radiological Health. EUA Authorized Serology Test Performance.
   2021. Available at: https://www.fda.gov/medical-devices/coronavirus-disease-2019-covid-19-emergency-use-authorizations-medical-devices/eua-authorized-serology-test-performance. Accessed 5 February 2021.
- 17. Tré-Hardy M, Wilmet A, Beukinga I, et al. Analytical and clinical validation of an ELISA for specific SARS-CoV-2 IgG, IgA, and IgM antibodies. J Med Virol **2021**; 93:803–811.
- 18. Trabaud M-A, Icard V, Milon M-P, Bal A, Lina B, Escuret V. Comparison of eight commercial, high-throughput, automated or ELISA assays detecting SARS-CoV-2 IgG or total antibody. J Clin Virol **2020**; 132:104613.
- Plaga A, Wei R, Olson E, et al. Evaluation of the Clinical Performance of 7 Serological Assays for SARS-CoV-2 for Use in Clinical Laboratories. J Appl Lab Med 2021; 6:998– 1004.
- 20. Sempos CT, Tian L. Adjusting Coronavirus Prevalence Estimates for Laboratory Test Kit Error. Am J Epidemiol **2021**; 190:109–115.
- 21. Tibshirani R. Regression Shrinkage and Selection via the Lasso. J R Stat Soc Series B Stat Methodol **1996**; 58:267–288.
- 22. Wilson N, Kvalsvig A, Barnard LT, Baker MG. Case-fatality risk estimates for COVID-19 calculated by using a lag time for fatality. Emerg Infect Dis **2020**; 26:1339–1441.
- 23. Nash D, Qasmieh S, Robertson M, et al. Household factors and the risk of severe COVID-like illness early in the US pandemic. medRxiv **2020**; Available at: http://dx.doi.org/10.1101/2020.12.03.20243683.
- 24. Lauer SA, Grantz KH, Bi Q, et al. The Incubation Period of Coronavirus Disease 2019 (COVID-19) From Publicly Reported Confirmed Cases: Estimation and Application. Ann Intern Med **2020**; 172:577–582.
- 25. Wang D, Hu B, Hu C, et al. Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus–Infected Pneumonia in Wuhan, China. JAMA **2020**; 323:1061–1069.
- Russell TW, Hellewell J, Jarvis CI, et al. Estimating the infection and case fatality ratio for coronavirus disease (COVID-19) using age-adjusted data from the outbreak on the Diamond Princess cruise ship, February 2020. Eurosurveillance. 2020; 25. Available at: http://dx.doi.org/10.2807/1560-7917.es.2020.25.12.2000256.

- 27. covid-19-data: An ongoing repository of data on coronavirus cases and deaths in the U.S. Github, Available at: https://github.com/nytimes/covid-19-data. Accessed 18 August 2021.
- 28. Madewell ZJ, Yang Y, Longini IM Jr, Halloran ME, Dean NE. Household Transmission of SARS-CoV-2: A Systematic Review and Meta-analysis. JAMA Netw Open **2020**; 3:e2031756.
- 29. Borrell LN, Elhawary JR, Fuentes-Afflick E, et al. Race and Genetic Ancestry in Medicine A Time for Reckoning with Racism. N Engl J Med **2021**; 384:474–480.
- 30. Mody A, Pfeifauf K, Geng EH. Using Lorenz Curves to Measure Racial Inequities in COVID-19 Testing. JAMA Netw Open **2021**; 4:e2032696.
- 31. Ogedegbe G, Ravenell J, Adhikari S, et al. Assessment of Racial/Ethnic Disparities in Hospitalization and Mortality in Patients With COVID-19 in New York City. JAMA Netw Open **2020**; 3:e2026881.
- 32. Nash D, Geng E. Goal-Aligned, Epidemic Intelligence for the Public Health Response to the COVID-19 Pandemic. Am J Public Health **2020**; 110:1154–1156.
- 33. Nash D. Designing and Disseminating Metrics to Support Jurisdictional Efforts to End the Public Health Threat Posed by HIV Epidemics. Am J Public Health **2020**; 110:53–57.
- 34. Bailey ZD, Feldman JM, Bassett MT. How Structural Racism Works Racist Policies as a Root Cause of U.S. Racial Health Inequities. N Engl J Med **2020**; Available at: http://dx.doi.org/10.1056/NEJMms2025396.
- 35. Bailey ZD, Krieger N, Agénor M, Graves J, Linos N, Bassett MT. Structural racism and health inequities in the USA: evidence and interventions. Lancet **2017**; 389:1453–1463.
- 36. Sullivan PS, Siegler AJ, Shioda K, et al. SARS-CoV-2 cumulative incidence, United States, August-December 2020. Clin Infect Dis **2021**; Available at: http://dx.doi.org/10.1093/cid/ciab626.
- 37. Scobie HM, Johnson AG, Suthar AB, et al. Monitoring Incidence of COVID-19 Cases, Hospitalizations, and Deaths, by Vaccination Status 13 U.S. Jurisdictions, April 4-July 17, 2021. MMWR Morb Mortal Wkly Rep **2021**; 70:1284–1290.
- 38. Rosenberg ES, Holtgrave DR, Dorabawila V, et al. New COVID-19 Cases and Hospitalizations Among Adults, by Vaccination Status New York, May 3-July 25, 2021. MMWR Morb Mortal Wkly Rep **2021**; 70:1306–1311.
- 39. Chia PY, Xiang Ong SW, Chiew CJ, et al. Virological and serological kinetics of SARS-CoV-2 Delta variant vaccine-breakthrough infections: a multi-center cohort study. bioRxiv. 2021; Available at: http://medrxiv.org/lookup/doi/10.1101/2021.07.28.21261295.

# **Supplemental Material**

Table S1. Baseline characteristics and serologic testing of CHASING COVID Cohort Study participants by time period of testing

	All participants		Participan one or n serologic te 2020-Janua	nore est (May	serologic Period 1	Participants with a serologic test in serologic Period 1 (May-September 2020) Participan Serologic 2020-January		
	N	%	N	%	N	%	N	%
Total	6,738	100%	4510	67%	4232	63%	3883	58%
Age								
Median (IQR)	37 (29,	51)	41 (31,	55)	41, (32,	56)	41, (32,	56)
18-29	1802	26.74	876	19.4	800	18.9	722	18.6
30-39	1955	29.01	1253	27.8	1171	27.7	1074	27.7
40-49	1163	17.26	858	19.0	812	19.2	738	19.0
50-59	792	11.75	658	14.6	620	14.7	582	15.0
60+	1026	15.23	865	19.2	829	19.6	767	19.8
Gender								
Male	3042	45.15	2018	44.8	1898	44.9	1738	44.8
Female	3525	52.32	2360	52.3	2211	52.2	2038	52.5
Non-Binary/Transgender	171	2.54	132	2.9	123	2.9	107	2.8
Race/Ethnicity								
Non-Hispanic White	3829	56.83	2966	65.8	2818	66.6	2568	66.1
Hispanic	1308	19.41	679	15.1	622	14.7	584	15.0
Non-Hispanic Black	848	12.59	378	8.4	341	8.1	316	8.1
Asian	439	6.52	286	6.3	262	6.2	245	6.3
Pacific Islander	36	0.53	18	0.4	18	0.4	16	0.4
Other	250	3.71	168	3.7	157	3.7	141	3.6
Missing	28	0.42	15	0.3	14	0.3	13	0.3
Education								
Less than high school	123	1.83	54	1.2	47	1.1	48	1.2
High school graduate	875	12.99	403	8.9	365	8.6	331	8.5
Some college	1888	28.02	1151	25.5	1052	24.9	954	24.6
College graduate	3852	57.17	2902	64.4	2768	65.4	2550	65.7
Employment								
Employed	4246	63.02	2774	61.5	2612	61.7	2394	61.7

Out of work	830	12.32	544	12.1	503	11.9	461	11.9
Homemaker	352	5.22	242	5.4	225	5.3	203	5.2
Student	608	9.02	367	8.1	329	7.8	305	7.9
Retired	702	10.42	583	12.9	563	13.3	520	13.4
Household income								
Less than \$35,000	1967	29.19	1186	26.3	1112	26.3	987	25.4
\$35-49,999	753	11.18	496	11.0	457	10.8	440	11.3
\$50-69,999	959	14.23	643	14.3	600	14.2	568	14.6
\$70-99,999	1058	15.7	741	16.4	706	16.7	660	17.0
\$100,000+	1793	26.61	1329	29.5	1258	29.7	1126	29.0
Missing	208	3.08	115	2.6	99	2.3	102	2.6
Setting								
Urban	2835	42.07	1911	42.4	1800	42.5	1642	42.3
Suburban	1792	26.59	1186	26.3	1119	26.4	1020	26.3
Rural	2049	30.41	1412	31.3	1312	31.0	1220	31.4
Missing	62	0.92	1	0.0	1	0.0	1	0.0
Geographic region								
Northeast	1891	28.06	1320	29.3	1253	29.6	1124	29.0
Midwest	1130	16.77	805	17.9	763	18.0	699	18.0
South	2040	30.28	1269	28.1	1168	27.6	1102	28.4
West	1630	24.19	1111	24.6	1043	24.7	954	24.6
US Territories	8	0.12	5	0.1	5	0.1	4	0.1
Missing	39	0.58	0	0.0	0	0.0	0	0.0
Healthcare worker								
No	5859	86.95	4048	89.8	3797	89.7	3492	89.9
Yes	795	11.8	425	9.4	400	9.5	355	9.1
Missing	84	1.25	37	8.0	35	0.8	36	0.9
Essential worker *								
No	4785	71.02	3170	70.3	2992	70.7	2700	69.5
Yes	1953	28.98	1340	29.7	1240	29.3	1183	30.5
Higher risk for severe COVID **								
No	3165	46.97	2097	46.5	1973	46.6	1797	46.3
Yes	3573	53.03	2413	53.5	2259	53.4	2086	53.7

<sup>\*</sup> Combined from three follow-up interviews between August and November 2020

<sup>\*\* &</sup>gt;60 years old, or reported co-morbidity, or current smoker. Comorbidity was defined as having history of heart attack, depression, angina, immunosuppression, type 2 diabetes, high blood pressure, cancer, asthma, COPD, chronic kidney disease, and/or HIV/AIDS

Table S2. Crude and adjusted\* serology-based cumulative incidence estimates of SARS-CoV-2 infection in CHASING COVID Cohort Study participants by time rich and adjusted serology-based cumulative incidence estimates of SARS-CoV-2 infection in CHASING COVID Cohort Study participants by time rich and adjusted serology-based cumulative incidence estimates of SARS-CoV-2 infection in CHASING COVID Cohort Study participants by time rich and adjusted serology-based cumulative incidence estimates of SARS-CoV-2 infection in CHASING COVID Cohort Study participants by time rich and adjusted serology-based cumulative incidence estimates of SARS-CoV-2 infection in CHASING COVID Cohort Study participants by time rich and adjusted serology-based cumulative incidence estimates of SARS-CoV-2 infection in CHASING COVID Cohort Study participants by time rich and adjusted serology-based cumulative incidence estimates of SARS-CoV-2 infection in CHASING COVID Cohort Study participants by time rich and adjusted serology-based cumulative incidence estimates and adjusted serology-based cumulative estimates and adjusted serology-based cumulative estimates and adjusted serology-based cumulative estimates and adjusted serology-based esti

			a serologic tes ember 2020) (N=			Participants with a serologic test in Period 2 (November 2020-January 2021) (N=3,883)					ne or more sero nuary 2021 (N=4,	
	Number positive	Total	Crude cumulative incidence (95% CI)	Adjusted cumulative incidence (95% CI)	Number positive	Total	Crude cumulative incidence (95% CI)	Adjusted cumulative incidence (95% CI)	Number positive	as not certifie	incidence (95% CI)	Adjusted cumulative incidence (95% CI)
Total	135	4232	3.2 (2.7, 3.7)	2.2 (1.7, 2.8)	286	3883	7.5 (6.7, 8.4)	7 (6.1, 8)	323	451	7.3 (6.5, 8.1)	6.7 (5.9, 7.6)
Age group										pe		
18-29	28	800	3.5 (2.2, 4.8)	2.5 (1.1, 4)	62	722	8.8 (6.7, 10.9)	8.4 (6.1, 10.7)	70	8₹6	8.2 (6.3, 10.0)	7.7 (5.6, 9.7)
30-39	46	1171	3.9 (2.8, 5.0)	3 (1.8, 4.2)	87	1074	8.3 (6.6, 10.0)	7.8 (6, 9.7)	100	1253 as 86	8.2 (6.6, 9.7)	7.7 (6, 9.4)
40-49	27	812	3.3 (2.3, 4.6)	2.3 (1.2, 4)	51	738	7.1 (5.2, 8.9)	6.5 (4.4, 8.5)	63	8 <del>8</del> 8	7.5 (5.7, 9.3)	7 (5, 9)
50-59	21	620	3.4 (2.0, 4.8)	2.4 (0.9, 4)	48	582	8.5 (6.2, 10.7)	8.1 (5.5, 10.5)	49	688	7.6 (5.6, 9.7)	7.1 (4.9, 9.4)
60+	13	829	1.6 (0.7, 2.4)	0.4 (0, 1.3)	38	767	5.1 (3.5, 6.6)	4.3 (2.5, 6)	41	865	4.8 (3.4, 6.3)	4 (2.4, 5.6)
Gender										istheauth e Saigble u	5	
Male	79	1898	4.2 (3.3, 5.1)	3.3 (2.3, 4.3)	151	1738	8.9 (7.6, 10.3)	8.5 (7.1, 10.1)	177	hogungder, wao I under 33 CC 197- 2 23	9.0 (7.7, 10.2)	8.6 (7.2, 9.9)
Female	55	2211	2.5 (1.8, 3.1)	1.4 (0.7, 2.1)	130	2038	6.5 (5.4, 7.6)	5.9 (4.6, 7.1)	141	2366	6.1 (5.2, 7.1)	5.4 (4.4, 6.5)
Non-										er, v		
Binary/Transgender	1	123	0.8 (0, 2.4)	0 (0, 1.3)	5	107	4.7 (0.7, 8.8)	3.9 (0, 8.4)	5	16	3.9 (0.5, 7.2)	3 (0, 6.6)
Race/Ethnicity										-\ha		
Non-Hispanic White	82	2818	2.9 (2.3, 3.5)	1.9 (1.2, 2.5)	170	2568	6.8 (5.8, 7.7)	6.2 (5.1, 7.2)	186	29 <mark>6</mark> 6	6.4 (5.5, 7.3)	5.7 (4.8, 6.7)
Hispanic	26	622	4.2 (2.6, 5.8)	3.3 (1.5, 5.1)	64	584	11.2 (8.6, 13.8)	11 (8.2, 13.9)	75	679 -	11.2 (8.8, 13.6)	11 (8.4, 13.7)
Non-Hispanic Black	13	341	3.8 (1.8, 5.8)	2.9 (0.7, 5.1)	28	316	9.2 (5.9, 12.4)	8.8 (5.2, 12.4)	32	378 8	8.7 (5.8, 11.6)	8.3 (5.1, 11.5)
Asian	9	262	3.4 (1.2, 5.6)	2.4 (0, 4.9)	13	245	5.5 (2.6, 8.4)	4.8 (1.5, 8)	16	286	5.7 (3.0, 8.5)	5 (2, 8.1)
Pacific Islander	0	18	0 (0, 21.8)	0 (0, 22.8)	0	16	0 (0, 24.1)	0 (0, 25.3)	0	<b>3</b> .8.2	0 (0, 24.1)	0 (0, 25.3)
Other	5	157	3.2 (0.4, 5.9)	1.9 (0, 4.8)	9	141	6.8 (2.5, 11.0)	7 (2.3, 11.7)	12	1 <u>8</u> 8 2	7.5 (3.4, 11.6)	7 (2.4, 11.5)
Missing	0	14	0 (0, 26.7)		2	13	15.4 (0, 35.0)		2	reisioni posied October 12, 2021. I has.graytedomedRayte allicense to -NC質ID4. Contenatio(組 license to 2	13.3 (0, 30.5)	
Education										esus Pasus Pasus		
Less than high school	3	47	6.4 (0, 13.4)	5.7 (0, 13.5)	6	48	12.8 (3.2, 22.3)	12.8 (2.2, 23.3)	6	.54 <u>6</u> -	11.3 (2.8, 19.9)	11.2 (1.8, 20.7)
High school grade	13	365	3.6 (1.7, 5.5)	2.7 (0.6, 4.8)	30	331	9.4 (6.2, 12.5)	9.1 (5.5, 12.5)	35	40% a Line 2007 i i i i i i i i i i i i i i i i i i	8.9 (6.1, 11.7)	8.5 (5.4, 11.6)
Some college	29	1052	2.8 (1.8, 3.8)	1.8 (0.7, 2.9)	70	954	7.5 (5.8, 9.2)	7 (5.3, 9.1)	79	115 🖺 🗧	7.0 (5.5, 8.5)	6.4 (4.8, 8.1)
College graduate	90	2768	3.3 (2.6, 3.9)	2.3 (1.5, 3)	180	2550	7.2 (6.2, 8.2)	6.6 (5.5, 7.7)	203	2902	7.1 (6.2, 8.1)	6.5 (5.5, 7.6)
Employment			,	, ,			,	,		brep	<u>,                                     </u>	,
Employed	95	2612	3.6 (3.0, 4.4)	2.7 (1.9, 3.5)	199	2394	8.5 (7.4, 9.7)	8.1 (6.9, 9.4)	221	277 <b>4</b> 2	8.1 (7.1, 9.2)	7.6 (6.5, 8.8)
Out of work	15	503	3.0 (1.5, 4.5)	2 (0.3, 3.6)	28	461	6.2 (4.0, 8.4)	5.5 (3.1, 8)	36	544 5	6.7 (4.6, 8.9)	6.1 (3.8, 8.5)
Homemaker	7	225	3.1 (0.8, 5.4)	2.1 (0, 4.6)	14	203	7.0 (3.5, 10.6)	6.4 (2.5, 10.4)	16	2425	6.7 (3.5, 9.9)	6.1 (2.5, 9.6)
Student	10	329	3.1 (1.6, 4.9)	2.1 (0, 4.1)	22	305	7.4 (4.4, 10.4)	6.9 (3.5, 10.2)	25	36₹.5	7.0 (4.4, 9.7)	6.4 (3.5, 9.4)
Retired	8	563	1.4 (0.4, 2.4)	0.2 (0, 1.3)	23	520	4.5 (2.7, 6.3)	3.6 (1.7, 5.6)	25	36 <b>½</b> 5	4.3 (2.7, 6.0)	3.4 (1.7, 5.3)

Household income										med		
Less than \$35,000	25	1112	2.3 (1.4, 3.1)	1.2 (0.2, 2.1)	66	987	6.9 (5.3, 8.5)	6.3 (4.5, 8.1)	74	118 <b>%</b> \(\frac{\partial}{\partial}\text{VEX}(\frac{\partial}{\part	6.4 (5.0, 7.8)	5.7 (4.2, 7.3)
\$35-49,999	17	457	3.7 (2.0, 5.4)	2.8 (0.9, 4.6)	40	440	9.3 (6.6, 12.1)	9 (6, 12)	43		8.8 (6.3, 11.4)	8.4 (5.6, 11.3)
\$50-69,999	16	600	2.7 (1.4, 4.0)	1.7 (0.2, 3.1)	35	568	6.3 (4.3, 8.3)	5.6 (3.4, 7.8)	41	496 Prepri	6.5 (4.6, 8.4)	5.9 (3.8, 8)
\$70-99,999	26	706	3.7 (2.3, 5.1)	2.8 (1.2, 4.3)	56	660	8.6 (6.5, 10.8)	8.2 (5.9, 10.6)	63	74 <mark>5</mark> a	8.6 (6.6, 10.7)	8.2 (6, 10.5)
\$100,000+	44	1258	3.5 (2.5, 4.5)	2.5 (1.4, 3.6)	79	1126	7.2 (5.7, 8.7)	6.6 (5, 8.3)	89	132 🖁 📴	6.8 (5.5, 8.2)	6.2 (4.8, 7.7)
Missing	7	99	7.3 (2.1, 12.5)		10	102	10.4 (4.3, 16.5)	(, )	13	115	11.9 (5.8, 18.0)	11.8 (5.1, 18.6)
Setting										<b>ed k</b>		
Urban	67	1800	3.7 (2.9, 4.6)	2.8 (1.9, 3.8)	121	1642	7.6 (6.3, 8.9)	7.1 (5.6, 8.5)	141	191 🛱 💆	7.5 (6.3, 8.7)	7 (5.6, 8.3)
Suburban	37	1119	3.3 (2.3, 4.4)	2.3 (1.2, 3.5)	78	1020	7.8 (6.1, 9.5)	7.3 (5.4, 9.2)	88	1186	7.6 (6.0, 9.1)	7.1 (5.3, 8.7)
Rural	31	1312	2.4 (1.5, 3.2)	1.3 (0.3, 2.2)	87	1220	7.3 (5.8, 8.8)	6.7 (5.1, 8.4)	94	14 2 2	6.8 (5.5, 8.1)	6.2 (4.8, 7.6)
Missing	0	1	0 (0,94.5)	0 (0, 100)	0	1	0 (0,94.5)	0 (0, 100)	0	0.1101/20 <b>[Aview)</b> 14 made	0 (0,94.5)	0 (0, 100)
Geographic region										a <u>v</u> . ≥		
Northeast	73	1253	5.8 (4.5, 7.1)	5.1 (3.8, 6.6)	93	1124	8.5 (6.9, 10.2)	8.1 (6.3, 9.9)	111	21.02.12.212510 the author/func value value 1 1 1	8.6 (7.1, 10.2)	8.2 (6.5, 9.9)
Midwest	16	763	2.1 (1.1, 3.1)	1 (0, 2.1)	53	699	7.7 (5.7, 9.7)	7.2 (5, 9.4)	54	8 1 N	6.8 (5.1, 8.6)	6.2 (4.3, 8.2)
South	31	1168	2.7 (1.7, 3.6)	1.7 (0.6, 2.7)	82	1102	7.6 (6.0, 9.2)	7.1 (5.3, 8.8)	96	12569 🛂	7.7 (6.2, 9.2)	7.2 (5.5, 8.8)
West	15	1043	1.4 (0.7, 2.2)	0.2 (0, 1.1)	58	954	6.2 (4.7, 7.8)	5.5 (3.9, 7.3)	62	114 6 2	5.7 (4.3, 7.1)	5 (3.4, 6.5)
US Territories	0	5	0 (0, 53.7)	0 (0, 58)	0	4	0 (0, 60.4)	0 (0, 65.4)	0	<b>6</b> 65 65 65 65 65 65 65 65 65 65 65 65 65	0 (0, 60.4)	0 (0, 65.4)
Healthcare worker										1659; this ades, who can CC-BY		
No	124	3797	3.3 (2.7, 3.8)	2.3 (1.7, 2.9)	255	3492	7.5 (6.6, 8.4)	7 (6, 8)	289	40 <u>4</u> 8	7.3 (6.5, 8.1)	6.7 (5.9, 7.6)
Yes	10	400	2.5 (1.0, 4.1)	1.4 (0.1, 3.5)	28	355	8.2 (5.3, 11.1)	7.7 (4.5, 10.9)	31	425 iš	7.5 (5.3, 10.4)	7 (4.5, 10.2)
Missing	1	35	2.9 (0, 8.4)	1.9 (0, 8)	3	36	8.3 (0, 17.4)	7.8 (0, 17.9)	3	s version poste o bas granted Yang Yang 2.01 4	8.1 (0, 16.9)	7.6 (0, 17.3)
Essential worker **										oste ed r		
No	86	2992	2.9 (2.3, 3.5)	1.9 (1.2, 2.5)	171	2700	6.5 (5.5, 7.4)	5.9 (4.8, 6.9)	196	317 6 0	6.3 (5.5, 7.2)	5.6 (4.8, 6.6)
Yes	49	1240	4.0 (2.9, 5.0)	3.1 (2, 4.4)	115	1183	10.0 (8.2, 11.7)	9.7 (7.7, 11.6)	127	ted Octob I med Revi 134 in 134 in 13	9.7 (8.1, 11.3)	9.4 (7.6, 11.2)
High Risk group ***										ona ona		
No	79	1973	4.0 (3.1, 4.9)	3.1 (2.1, 4.1)	153	1797	8.7 (7.4, 10.0)	8.3 (6.9, 9.7)	174	2097 10 10	8.5 (7.3, 9.7)	8.1 (6.7, 9.4)
Yes	56	2259	2.5 (1.8, 3.1)	1.4 (0.8, 2.2)	133	2086	6.5 (5.5, 7.6)	5.9 (4.8, 7.1)	149	24 3 3 202	6.3 (5.3, 7.3)	5.6 (4.5, 6.7)
Changes in community tran	smission									." of . <del>1</del>		
Median (IQR)	0.17 (0.06, 0.46)				0.27 (0.16, 0.44)					The displ		
High	81	1412	5.7 (4.5, 7.0)	5 (3.6, 6.4)	119	1297	9.5 (7.9, 11.1)	9.2 (7.4, 10.9)	N/A	N/A∰ c	N/A	N/A
Medium	34	1410	2.4 (1.6, 3.2)	1.3 (0.4, 2.2)	92	1294	7.3 (5.9, 8.7)	6.7 (5.2, 8.3)	N/A	N/Ag	N/A	N/A
Low	20	1410	1.4 (0.8, 2.0)	0.2 (0, 0.9)	75	1292	5.9 (4.6, 7.2)	5.2 (3.8, 6.6)	N/A	N/Æ	N/A	N/A

<sup>\*</sup>Adjusted for test sensitivity and specificity

\*\* Combined from three follow-up interviews between August and November 2020

\*\*\* >60 years old, or reported co-morbidity, or current smoker. Comorbidity was defined as having history of heart attack, depression, angina, immunosuppression, type 2 diabetes, high blood pressure, cancer, asthma, COPD, chronic kidney disease, and/or HIV/AIDS




Figure S1. Geographic distribution of CHASING COVID Cohort participants, N=6,738

Figure S2. Timing of first (red) and second (blue) dried blood spot specimen collection in the CHASING COVID Cohort Study, including follow-up interview milestones

